2 results match your criteria: "University Hospital Friuli Centrale ASU FC[Affiliation]"
Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure.
Biomed Pharmacother
August 2023
Experimental and Clinical Pharmacology Unit-CRO Aviano, National Cancer Institute, IRCCS, Aviano, Italy. Electronic address:
Article Synopsis
- * Patients with a BMI under 25 experienced more severe hematologic toxicities, required more dose reductions, and had shorter progression-free survival compared to those with a BMI of 25 or higher.
- * The findings suggest that BMI might be an important factor in personalizing treatment by adjusting the starting dose of palbociclib to enhance safety and effectiveness.
Therapeutic Drug Monitoring of Mycophenolic Acid as a Precision Medicine Tool for Heart Transplant Patients: Results of an Observational Pharmacokinetic Pilot Study.
Pharmaceutics
June 2022
Clinical Pharmacology and Toxicology Institute, University Hospital Friuli Centrale ASU FC, 33100 Udine, Italy.
In the clinical practice management of heart transplant (HTx), the impact of calcineurin inhibitors co-administration on pharmacokinetics (PKs) of mycophenolic acid (MPA), mycophenolate mofetil (MMF) active drug, is not adequately considered. This retrospective study investigated full MPA-PK profiles by therapeutic drug monitoring (TDM) in 21 HTx recipients treated with MMF combined with cyclosporine (CsA) or tacrolimus (TAC) at a median time of 2.6 months post-transplant.
View Article and Find Full Text PDF